ENGENSIS
LIVE

Serial Number

87777607

Owner

HELIXMITH CO., LTD

Attorney

Daniel P. Mullarkey

Filing Date

Jan 31, 2018

Add to watchlist:

No watchlists yet
View on USPTO

ENGENSIS Trademark

Serial Number: 87777607 • Registration: 5694789

ENGENSIS is a trademark filed by HELIXMITH CO., LTD on January 31, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

HELIXMITH CO., LTD (5 trademarks)

1 GWANAK-RO 5TH FL. BLDG. 203
SEOUL 08826 , KR

Entity Type: 03

ViroMed Co., Ltd. (5 trademarks)

5th Fl.Bldg. 203, Seoul Nat'l University
Seoul 08826 , KR

Entity Type: 03

Trademark Details

Filing Date

January 31, 2018

Registration Date

March 12, 2019

Published for Opposition

October 2, 2018

Goods & Services

Chemical reagents for use in veterinary genetic testing; reagents for use in medical genetic testing; diagnostic preparations for medical purposes for detecting mutation in prion genes; preparations for medical purposes for detecting mutation in prion genes; chemical preparations for pharmaceutical purposes, namely, for painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; drugs for medical purposes, namely, prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; pharmaceutical preparations for the treatment of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; medicines for human purposes, namely, pharmaceutical preparations for the treatment of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; pharmaceutical preparations for diagnosis of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; ethical medicinal preparations, namely, pharmaceutical preparations for the treatment of painful diabetic neuropathy, neuropathy, neuromuscular disease, amyotrophic lateral sclerosis, spinal cord disease, motor neuron disease, neurodegenerative disease, critical limb ischemia, diabetic foot ulcer, ulcer, cardiovascular disease, peripheral vascular disease, peripheral arterial disease, myocardial ischemia, coronary artery disease, heart disease, arterial occlusive disease, infarction; pharmaceutical preparations for the treatment of immune system related diseases and disorders; chemical preparations for use in medical DNA analysis; genetic treatment pharmaceutical preparations

Pharmaceutical research and development; pharmaceutical research services; consultancy relating to pharmaceutical research and development; research and development of vaccines and medicines; scientific research in the fields of biomedicine; research and testing services in the fields of bacteriology and virology; drug discovery services; research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; consultancy in analysis of biology sequence processing for medical research purposes; consultancy in analysis of genomics for medical research purposes; scientific research in the fields of medicine, health and pharmacology; analysis of human serum for medical research; analysis of human tissues for medical research; blood analysis services

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Jun 9, 2025 NA85
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Jun 9, 2025 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jun 9, 2025 APRE
TEAS SECTION 8 & 15 RECEIVED
Feb 13, 2025 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Mar 12, 2024 REM1
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jun 19, 2019 ASGN
REVIEW OF CORRESPONDENCE COMPLETE - CERTIFICATE OF REG MAILED
May 10, 2019 CORV
REGISTERED-PRINCIPAL REGISTER
Mar 12, 2019 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Feb 5, 2019 DP1B
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 5, 2019 AITU
NOTICE OF ALLOWANCE CANCELLED
Dec 21, 2018 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Dec 21, 2018 D1BR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 27, 2018 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 2, 2018 NPUB
PUBLISHED FOR OPPOSITION
Oct 2, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 12, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 24, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 23, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 23, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 23, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 14, 2018 GNRN
NON-FINAL ACTION E-MAILED
May 14, 2018 GNRT
NON-FINAL ACTION WRITTEN
May 14, 2018 CNRT
ASSIGNED TO EXAMINER
May 14, 2018 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
May 1, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 1, 2018 CRFA
ASSIGNED TO LIE
May 1, 2018 ALIE
TEAS VOLUNTARY AMENDMENT RECEIVED
Apr 24, 2018 PARI
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 9, 2018 NWOS
NEW APPLICATION ENTERED
Feb 3, 2018 NWAP